News articles

  • Blood Tests: Not Just for the Impaired?

    In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease... Read more...
  • Looking Good: Immunoassays for Blood Markers

    For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical... Read more...
  • More opportunities to test for Alzheimer’s using new analytical method

    A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led... Read more...
  • Simple, yet effective way to early detect Alzheimer’s disease

    A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led... Read more...
  • How dementia affects the brain’s ability to empathize

    Patients with frontotemporal dementia often lack the ability to feel empathy. A study at Lund University and the Karolinska... Read more...
  • Reading the signs of dementia

    In this Nature outlook the BioFINDER study group’s work on how blood tests are leading to earlier diagnosis, and... Read more...
Load more

Recent key publications

More publications...

X posts

🚨New paper alert! This study led by @SEMastenbroek aims to make detection of α-synuclein pathology in the brain more time- and cost-effective. Out now in Nature Communications! 🔗 Full article: https://www.nature.com/articles/s41467-025-62458-7.epdf?sharing_token=fJsM7nw6WLFQSLEmJtlXiNRgN0jAjWel9jnR3ZoTv0MDVkWnZxGsgtCMfY18v2PG-JBJvKhRsSwlFHbyWcVEhi_UdJDYtyqFZKb0-1LE-RJuxLzTxso4Wsn_ZLSgyRQKvtbjLPDfKEVHUrWMYnYD648e1kcTBiQcj_tBKohdF6g%3D
A thread🧵👇

6/🧵Taken together, we present an accurate two-step approach for predicting LBP in the brain using a smell test followed by CSF SAA testing in smell-test positive individuals. This could minimize costs, reduce patient burden, and improve the known underdiagnosis of DLB and PD.

A huge thanks to all authors and collaborators who made this work possible! @OskarHansson9 @LECollij @_JakeVogel_ @SebastianPalmqv @FBarkhof @RikOssenkoppele and all not on X.

7⃣This suggests that region-specific atrophy functions as one pathway of tau-induced cognitive subdomain impairments. Yet, large portions of variance remains unexplained, highlighting the need for investigating other mechanistic links.🔬

8⃣A huge thank you to all authors as well as the #ADNI study participants who made this work possible. Your contributions are vital for advancing our understanding of the disease and contribute to #ENDALZ.

6⃣Do certain regions uniquely mediate a given tau-cognition association? - Yes, tau–immediate recall was mediated by several MTL regions, tau–recognition by hippocampus & tau–semantic fluency by inferior temporal gyrus.

In conclusion, p-Tau217ALZpath exhibited similar performance to p-Tau181Lilly, but its correlations with AD pathology measures were significantly lower than p-Tau217Lilly. Future studies are needed to replicate these findings in larger cohorts.

Big thanks to all the co-authors for their invaluable contributions: @gesalbla, Thomas Beach, Geidy Serrano, Alireza Atri, Eric Reiman, Andreas Jeromin, @OskarHansson9, and Shorena Janelidze.

7⃣These findings support implementation of especially plasma p-tau217, and potentially also GFAP, in prognostic workup of AD in people with DS in both clinical practice and drug trials.

🚨Exciting new preprint from a great collaboration between our group and the talented PhD student @jorittmo from @_JakeVogel_'s group! They investigate how the 🧠 reorganises in the context of age and AD. Dive into the details here 🧵👇

Twitter feed video.
Jonathan Rittmo @jorittmo

How does the brain reorganize in the context of age and AD?

Are functional changes in age and AD similar?

Are these changes dynamic across the age/AD spectrum?

We unpack these questions in a sample of N=973 with AD biomarkers

Preprint: http://tinyurl.com/ymv8s7h8

1/
⬇️🧵

So excited and honored to be invited to present the opening plenary at #AIC2025 this year in Toronto! 🧠

🙏 I would be very grateful if you could help me gather the most inspiring papers (including your own!) of the past year by completing this survey: https://alz.surveymonkey.com/r/923BTQK

6/🧵Concluding, plasma assays specific for LMW p-tau are preferable in the diagnostic workup of AD, with fewer false positive findings, especially in diverse population-based communities where peripheral neuropathy may produce high p-tau levels when using non-LMW specific assays.

A big thank you to all our collaborators from Bologna, Umeå, and Gothenburg and a special thanks to all co-authors @NicholasAshton @A_OrdunaDolado @DivyaBali06 @NiklasMattsson4 @OskarHansson9
and all not on X!

6/🧵Our findings suggest that regional vulnerability to Aβ, not reduced inter-hemispheric connectivity, drives asymmetric tau accumulation in AD. This strengthens the link between Aβ and tau and supports the evidence of early anti-Aβ interventions to help limit tau buildup.

Big thanks to all co-authors and collaborators!
@RikOssenkoppele @ErikRubenSmith @LECollij @aitchbi @jorittmo @karlssonlinda1 @DaniellevWe @_JakeVogel_ @EStomrud @SebastianPalmqv @NiklasMattsson4 @NicolaSpotorno @OskarHansson9 + those not on X

Load More